Literature DB >> 34319130

Long-Term Evolution of SARS-CoV-2 in an Immunocompromised Patient with Non-Hodgkin Lymphoma.

Vítor Borges1, Joana Isidro1, Mário Cunha2, Daniela Cochicho2, Luís Martins2, Luís Banha2, Margarida Figueiredo2, Leonor Rebelo2, Maria Céu Trindade3, Sílvia Duarte4, Luís Vieira4, Maria João Alves5, Inês Costa6, Raquel Guiomar6, Madalena Santos7, Rita Cortê-Real7, André Dias8, Diana Póvoas8, João Cabo8, Carlos Figueiredo8, Maria José Manata8, Fernando Maltez8, Maria Gomes da Silva3, João Paulo Gomes1.   

Abstract

Recent studies have shown that persistent SARS-CoV-2 infections in immunocompromised patients can trigger the accumulation of an unusual high number of mutations with potential relevance at both biological and epidemiological levels. Here, we report a case of an immunocompromised patient (non-Hodgkin lymphoma patient under immunosuppressive therapy) with a persistent SARS-CoV-2 infection (marked by intermittent positivity) over at least 6 months. Viral genome sequencing was performed at days 1, 164, and 171 to evaluate SARS-CoV-2 evolution. Among the 15 single-nucleotide polymorphisms (SNPs) (11 leading to amino acid alterations) and 3 deletions accumulated during this long-term infection, four amino acid changes (V3G, S50L, N87S, and A222V) and two deletions (18-30del and 141-144del) occurred in the virus Spike protein. Although no convalescent plasma therapy was administered, some of the detected mutations have been independently reported in other chronically infected individuals, which supports a scenario of convergent adaptive evolution. This study shows that it is of the utmost relevance to monitor the SARS-CoV-2 evolution in immunocompromised individuals, not only to identify novel potentially adaptive mutations, but also to mitigate the risk of introducing "hyper-evolved" variants in the community. IMPORTANCE Tracking the within-patient evolution of SARS-CoV-2 is key to understanding how this pandemic virus shapes its genome toward immune evasion and survival. In the present study, by monitoring a long-term COVID-19 immunocompromised patient, we observed the concurrent emergence of mutations potentially associated with immune evasion and/or enhanced transmission, mostly targeting the SARS-CoV-2 key host-interacting protein and antigen. These findings show that the frequent oscillation in the immune status in immunocompromised individuals can trigger an accelerated virus evolution, thus consolidating this study model as an accelerated pathway to better understand SARS-CoV-2 adaptive traits and anticipate the emergence of variants of concern.

Entities:  

Keywords:  SARS-CoV-2; convergent evolution; genome sequencing; immunocompromised host; long-term infection

Year:  2021        PMID: 34319130     DOI: 10.1128/mSphere.00244-21

Source DB:  PubMed          Journal:  mSphere        ISSN: 2379-5042            Impact factor:   4.389


  15 in total

Review 1.  Identifying Markers of Emerging SARS-CoV-2 Variants in Patients With Secondary Immunodeficiency.

Authors:  Nathan M Markarian; Gaël Galli; Dhanesh Patel; Mark Hemmings; Priya Nagpal; Albert M Berghuis; Levon Abrahamyan; Silvia M Vidal
Journal:  Front Microbiol       Date:  2022-07-01       Impact factor: 6.064

2.  Accelerated SARS-CoV-2 intrahost evolution leading to distinct genotypes during chronic infection.

Authors:  Chrispin Chaguza; Anne M Hahn; Mary E Petrone; Shuntai Zhou; David Ferguson; Mallery I Breban; Kien Pham; Mario A Peña-Hernández; Christopher Castaldi; Verity Hill; Wade Schulz; Ronald I Swanstrom; Scott C Roberts; Nathan D Grubaugh
Journal:  medRxiv       Date:  2022-07-02

3.  The Ukrainian refugee crisis and the COVID-19 pandemic in Europe.

Authors:  Farid Rahimi; Amin Talebi Bezmin Abadi
Journal:  Int J Surg       Date:  2022-05-13       Impact factor: 13.400

4.  Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Sequence Characteristics of Coronavirus Disease 2019 (COVID-19) Persistence and Reinfection.

Authors:  Manish C Choudhary; Charles R Crain; Xueting Qiu; William Hanage; Jonathan Z Li
Journal:  Clin Infect Dis       Date:  2022-01-29       Impact factor: 9.079

5.  SARS-CoV-2 variants in immunocompromised COVID-19 patients: The underlying causes and the way forward.

Authors:  N Bansal; M Raturi; Y Bansal
Journal:  Transfus Clin Biol       Date:  2021-12-29       Impact factor: 2.126

6.  Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review.

Authors:  Daniele Focosi; Fabrizio Maggi; Massimo Franchini; Scott McConnell; Arturo Casadevall
Journal:  Int J Mol Sci       Date:  2021-12-21       Impact factor: 5.923

7.  Cumulative SARS-CoV-2 mutations and corresponding changes in immunity in an immunocompromised patient indicate viral evolution within the host.

Authors:  Sissy Therese Sonnleitner; Martina Prelog; Stefanie Sonnleitner; Eva Hinterbichler; Hannah Halbfurter; Dominik B C Kopecky; Giovanni Almanzar; Stephan Koblmüller; Christian Sturmbauer; Leonard Feist; Ralf Horres; Wilfried Posch; Gernot Walder
Journal:  Nat Commun       Date:  2022-05-10       Impact factor: 17.694

8.  Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection.

Authors:  Andreas Heyer; Thomas Günther; Alexis Robitaille; Marc Lütgehetmann; Marylyn M Addo; Dominik Jarczak; Stefan Kluge; Martin Aepfelbacher; Julian Schulze Zur Wiesch; Nicole Fischer; Adam Grundhoff
Journal:  Cell Rep Med       Date:  2022-08-16

9.  Mutational induction in SARS-CoV-2 major lineages by experimental exposure to neutralising sera.

Authors:  Martina Brandolini; Giorgio Dirani; Francesca Taddei; Silvia Zannoli; Agnese Denicolò; Valentina Arfilli; Arianna Battisti; Martina Manera; Andrea Mancini; Laura Grumiro; Maria Michela Marino; Giulia Gatti; Michela Fantini; Simona Semprini; Vittorio Sambri
Journal:  Sci Rep       Date:  2022-07-21       Impact factor: 4.996

Review 10.  The Immune Response to SARS-CoV-2 and Variants of Concern.

Authors:  Elham Torbati; Kurt L Krause; James E Ussher
Journal:  Viruses       Date:  2021-09-23       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.